See related research by Di Somma *et al*., <http://ccforum.com/content/17/1/R29>

Biomarkers are tools that should aid the physician in diagnosis, in risk stratification with prediction of outcome, and, at best, in clinical decision-making \[[@B1]\]. Because the usual renal biomarkers (for example, serum creatinine and/or urine output) may fail to detect acute kidney injury (AKI) at early onset, there is a current effort to search for and validate new diagnostic biomarkers. Neutrophil gelatinase-associated lipocalin (NGAL) is one of the most promising candidates because its level of expression in renal tissue increases dramatically after ischemia-reperfusion injury but not in the case of pure pre-renal failure \[[@B2]\]. Those data suggest the ability of NGAL to detect renal structural damage. Although first studies have highlighted that NGAL monitoring would perform better than standard biomarkers in detecting or quantifying AKI, other reports have yielded conflicting results and raised concerns regarding the accuracy of NGAL for this purpose \[[@B3]\].

In this context, the study published by Di Somma and colleagues in *Critical Care*provides important additional insights \[[@B1]\]. The study included patients admitted to hospital from the emergency room, to assess the diagnosis and prognosis value of plasmatic NGAL using a point-of-care method. The authors attempted a multidimensional approach including the NGAL level combined with the initial clinical assessment of risk of presumed AKI by the caring physician. In a Net Reclassification Improvement analysis, NGAL improved classification of AKI by 32.4%. This improvement occurred mainly by moving patients from the AKI to the no-AKI subgroups. NGAL was confirmed to have a high predictive negative value in this population with low prevalence of AKI.

At first glance, these results suggest that NGAL has an additional diagnostic value to clinical suspicion, which is a crucial requirement for a new biomarker to improve the predictive accuracy of the standard of care. Looking deeper, this study highlights concerns regarding the clinical validation of biomarkers of renal injury. Interestingly, the authors excluded acute renal dysfunctions from AKI, a classification that referred to a subset of disease characterized by transient decline of the glomerular filtration rate with presumed no or minor structural damage (similarly to pre-renal AKI) \[[@B4]\]. This study adds evidence to the recent study from Nejat and colleagues that these classifications based on clinical presumption may be erroneous, with increased serum levels of both biomarkers of renal function and injury in these subsets of patients \[[@B5]\]. Using classifications based on markers of glomerular function (Acute Kidney Injury Network/Risk Injury Failure Loss Endstage/Kidney Disease: Improving Global Outcomes) to validate biomarkers of renal injury introduces the risk of diverting such biomarkers from their true goal and significance, namely to detect organ damage. Using classifications based on a clinical assumption of pure pre-renal mechanism of renal failure obviously further exposes the patient to misclassification of outcome. Although an association exists between organ injury and the inherent loss of function, the relationship is obviously complex and may vary with respect to the causative process \[[@B6],[@B7]\].

The influence of comorbidities adds further complexity. Intriguingly, urine NGAL has been associated with long-term cardiovascular mortality in a cohort of older community-dwelling adults with no past history of clinical cardiovascular disease with a median level of 192 ng/ml, higher than the threshold proposed for detection of AKI in the study by Di Somma and colleagues (that is, 150 ng/ml), reflecting a high noise/signal ratio for the diagnosis of renal failure (which semantically better defines altered glomerular function) \[[@B8]\]. The expectation that a single biomarker (with a much hunted critical threshold) could at the same time capture these mechanisms of disease and could accurately predict the loss of function and/or stage of kidney injury is therefore obviously flawed. By analogy, who would expect increased serum troponin to accurately detect or predict heart failure? Other (bio)markers can do so.

NGAL carries risk information beyond markers of renal function and clinical assessment. In the present study NGAL did not perform better than the estimated glomerular filtration rate or clinical judgment, which share common criteria with the clinical endpoint (namely serum creatinine and estimated glomerular filtration rate) - further suggesting that these biomarkers provide different information, including a prognostic value \[[@B9]\]. Is it time for intensivists to operate the paradigm shift at the bedside in the way we assess AKI by using NGAL to monitor renal damage? Further exploration of the association between biomarkers of renal function, biomarkers of renal injury and prognosis appears a crucial next step before doing so. The results of an ongoing large multicenter study assessing the association between NGAL and 1-year outcome in ICU patients will provide important insights into this issue (FROG-ICU trial, ClinicalTrials.gov:NCT01367093). Exploration of the links between hits, damage and driving forces of renal failure through the sources of different biomarkers \[[@B1]\], identification of the NGAL pathways (that is, systemic inflammation, chronic renal injury, acute renal injury, and so forth) \[[@B10]\] and increased specificity of biomarkers toward renal injury is then required \[[@B11],[@B12]\] (Figure [1](#F1){ref-type="fig"}). Most importantly, intensivists and emergency physicians should explore whether risk stratification using NGAL will translate in clinical decision-making.

![**Serum/urine neutrophil-gelatinase associated lipocalin increase might outweigh renal function biomarkers for prediction of adverse outcome**. Several lines of evidence suggest that a rise of serum or urine level of neutrophil-gelatinase associated lipocalin (NGAL) might outweigh biomarkers of renal function for prediction of adverse outcome (that is, mortality). Further prospective studies should confirm these findings. Dashed lines enclose potential effectors linking biomarkers of renal function (for example, serum creatinine) and renal injury (for example, NGAL) to poor outcome. These factors can affect the serum level of these biomarkers (+) but can also influence outcome (-). Further research should explore the significance of these associations and will unveil the specificity of the biomarkers toward renal injury.](cc12578-1){#F1}

In conclusion, current definitions of AKI are based on renal function biomarkers that carry different information than biomarkers of injury. NGAL can detect renal injury, and does so pretty well. Injury does not always translate into renal failure, however, and the converse holds true. Future research should aim at clarifying what we are really looking at with biomarkers of kidney injury, including NGAL, and what are the clinical implications. Pending these advancements, we certainly have to accept that injury is not function and that in most conditions trying to predict renal failure with biomarkers of injury will remain an elusive task.
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